{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:25:14Z","timestamp":1793982314122,"version":"4.8.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005614","name":"Biogen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005614","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ekir.2026.106468","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:35:25Z","timestamp":1773362125000},"page":"106468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Prospective Cohort Study of Felzartamab in Rituximab-Resistant Primary Membranous Nephropathy"],"prefix":"10.1016","volume":"11","author":[{"given":"Matias","family":"Trillini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Casiraghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Gennarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Portalupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maddalena","family":"Maras\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel Alfredo","family":"Podest\u00e0","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Prandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Nozza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Todeschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Pecoraro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilena","family":"Mister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Stucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobia","family":"Peracchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Fidone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Rubis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olimpia","family":"Diadei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Martinetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Remuzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piero","family":"Ruggenenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2026.106468_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrneph.2017.92","article-title":"Treatment of membranous nephropathy: time for a paradigm shift","volume":"13","author":"Ruggenenti","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.ekir.2026.106468_bib2","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1056\/NEJM199307083290203","article-title":"Prognosis of untreated patients with idiopathic membranous nephropathy","volume":"329","author":"Schieppati","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106468_bib3","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2026.106468_bib4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106468_bib5","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1681\/ASN.2020071082","article-title":"New \u201cantigens\u201d in membranous nephropathy","volume":"32","author":"Sethi","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106468_bib6","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1681\/ASN.2014070640","article-title":"Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy","volume":"26","author":"Ruggenenti","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106468_bib7","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106468_bib8","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106468_bib9","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106468_bib10","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1681\/ASN.2016091022","article-title":"Safety of rituximab compared with steroids and cyclophosphamide for idiopathic membranous nephropathy","volume":"28","author":"van den Brand","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106468_bib11","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.kint.2021.05.015","article-title":"Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases","volume":"100","author":"Rovin","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2026.106468_bib12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s40265-023-01855-y","article-title":"Update on the application of monoclonal antibody therapy in primary membranous nephropathy","volume":"83","author":"Deng","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.ekir.2026.106468_bib13","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106468_bib14","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1053\/j.ajkd.2023.08.010","article-title":"Ofatumumab in rituximab-resistant and rituximab-intolerant patients with primary membranous nephropathy: a case series","volume":"83","author":"Podest\u00e0","year":"2024","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.ekir.2026.106468_bib15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","article-title":"Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow","volume":"43","author":"Halliley","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.ekir.2026.106468_bib16","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood.V99.6.2154","article-title":"The heterogeneity shown by human plasma cells from tonsil, blood, and bone marrow reveals graded stages of increasing maturity, but local profiles of adhesion molecule expression","volume":"99","author":"Medina","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2026.106468_bib17","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/imr.13013","article-title":"Plasma cell survival: the intrinsic drivers, migratory signals, and extrinsic regulators","volume":"303","author":"Nguyen","year":"2021","journal-title":"Immunol Rev"},{"issue":"Suppl 1","key":"10.1016\/j.ekir.2026.106468_bib18","doi-asserted-by":"crossref","DOI":"10.1186\/ar3908","article-title":"B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies","volume":"15","author":"Leandro","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ekir.2026.106468_bib19","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ekir.2022.12.011","article-title":"Novel treatments paradigms: membranous nephropathy","volume":"8","author":"Rojas-Rivera","year":"2023","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106468_bib20","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1182\/blood.V126.23.3015.3015","article-title":"MOR202, a human anti-CD38 monoclonal antibody, mediates potent tumoricidal activity in vivo and shows synergistic efficacy in combination with different antineoplastic compounds","volume":"126","author":"Boxhammer","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ekir.2026.106468_bib21","doi-asserted-by":"crossref","first-page":"835","DOI":"10.3389\/fimmu.2018.00835","article-title":"Targeting B cells and plasma cells in autoimmune diseases","volume":"9","author":"Hofmann","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2026.106468_bib22","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.ekir.2024.06.018","article-title":"Phase 1b\/2a study assessing the safety and efficacy of felzartamab in anti-phospholipase A2 receptor autoantibody-positive primary membranous nephropathy","volume":"9","author":"Rovin","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106468_bib23","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/cpt.2602","article-title":"Science-based approach to harmonize contraception recommendations in clinical trials and pharmaceutical labels","volume":"113","author":"Bowman","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ekir.2026.106468_bib24","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1007\/s40620-018-0533-z","article-title":"Definition of a new cut-off for the anti-phospholipase A2 receptor (PLA2R) autoantibody immunoassay in patients affected by idiopathic membranous nephropathy","volume":"31","author":"Tampoia","year":"2018","journal-title":"J Nephrol"},{"key":"10.1016\/j.ekir.2026.106468_bib25","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.cca.2013.03.015","article-title":"Development of a standardized ELISA for the determination of autoantibodies against human M-type phospholipase A2 receptor in primary membranous nephropathy","volume":"421","author":"D\u00e4hnrich","year":"2013","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ekir.2026.106468_bib26","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1681\/ASN.V62257","article-title":"Plasma clearance of nonradioactive iohexol as a measure of glomerular filtration rate","volume":"6","author":"Gaspari","year":"1995","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2026.106468_bib27","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/cyto.a.24507","article-title":"Comprehensive phenotyping of human peripheral blood B lymphocytes in healthy conditions","volume":"101","author":"Carsetti","year":"2022","journal-title":"Cytom A"},{"key":"10.1016\/j.ekir.2026.106468_bib28","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa2400763","article-title":"A randomized Phase 2 trial of felzartamab in antibody-mediated rejection","volume":"391","author":"Mayer","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ekir.2026.106468_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543784.2025.2463092","article-title":"CD38 monoclonal antibody felzartamab for late antibody-mediated rejection: a phase II drug evaluation","volume":"34","author":"Mayer","year":"2025","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ekir.2026.106468_bib30","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.ekir.2022.05.031","article-title":"Immunologic responses after COVID-19 vaccination in patients with membranous nephropathy receiving anti-CD38 felzartamab therapy: results from the phase 1b\/2a M-PLACE Study","volume":"7","author":"Rovin","year":"2022","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.ekir.2026.106468_bib31","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1111\/imr.12011","article-title":"The establishment of the plasma cell survival niche in the bone marrow","volume":"251","author":"Chu","year":"2013","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ekir.2026.106468_bib32","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1159\/000501460","article-title":"The role of long-lived plasma cells in antibody-mediated rejection of kidney transplantation: an update","volume":"5","author":"Su","year":"2019","journal-title":"Kidney Dis (Basel)"},{"key":"10.1016\/j.ekir.2026.106468_bib33","doi-asserted-by":"crossref","first-page":"788","DOI":"10.3389\/fimmu.2019.00788","article-title":"In the right place, at the right time: spatiotemporal conditions determining plasma cell survival and function","volume":"10","author":"Lindquist","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ekir.2026.106468_bib34","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.kint.2021.12.019","article-title":"Daratumumab for multidrug-resistant phospholipase-A2 receptor-related membranous nephropathy","volume":"101","author":"Vink","year":"2022","journal-title":"Kidney Int"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926027002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024926027002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:22:20Z","timestamp":1780478540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024926027002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2468024926027002"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106468","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prospective Cohort Study of Felzartamab in Rituximab-Resistant Primary Membranous Nephropathy","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2026.106468","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier, Inc., on behalf of the International Society of Nephrology.","name":"copyright","label":"Copyright"}],"article-number":"106468"}}